What is the safety and efficacy record of Hospiras Retacrit?
Hospira presented data at three European conferences in late 2008 showing that Retacrit is comparable in effectiveness to other EPO products in treating patients with chronic kidney disease, end-stage renal failure associated with diabetic neuropathy and chemotherapy-induced anemia. These were very convincing studies that involved large numbers of patients. Almost 1,000 years of Retacrit exposure was generated during clinical trials. This is identical to the number of patient years that the original EPO product generated to gain FDA approval. There have been no safety issues with Retacrit, which has been on the market in Europe for over a year.
